Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Mult Scler
; 27(12): 1960-1964, 2021 10.
Article
in En
| MEDLINE
| ID: mdl-34165361
ABSTRACT
BACKGROUND:
Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. OBJECTIVE ANDRESULTS:
Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.CONCLUSION:
Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Glomerulonephritis
/
Multiple Sclerosis
Limits:
Humans
Language:
En
Journal:
Mult Scler
Year:
2021
Document type:
Article